A new preclinical study from researchers at The University of Texas MD Anderson Cancer Center, published in Nature Communications, identifies a powerful strategy to overcome drug resistance in breast ...
An enzyme called cyclin-dependent kinase 2 (CDK2) regulates the cell cycle and may have the potential to drive therapeutic resistance to common breast cancer drugs—including a class of targeted ...
WALTHAM, Mass.--(BUSINESS WIRE)--Ensem Therapeutics, Inc. (ENSEM), a pioneering drug discovery and development company that leverages its unique Kinetic Ensemble® platform to advance innovative small ...
This preclinical study explains the mechanism underlying CDK2 and CDK4/6 combination therapy, providing a blueprint for future clinical use These findings are notable because several CDK2 inhibitor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results